Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy.

Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M.

J Clin Med. 2019 Sep 25;8(10). pii: E1534. doi: 10.3390/jcm8101534. Review.

2.

Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes.

Kubasch AS, Platzbecker U.

Int J Mol Sci. 2019 Aug 7;20(16). pii: E3853. doi: 10.3390/ijms20163853. Review.

3.

The wolf of hypomethylating agent failure: what comes next?

Kubasch AS, Platzbecker U.

Haematologica. 2019 Aug;104(8):1505-1508. doi: 10.3324/haematol.2019.222794. No abstract available.

4.

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M.

Sci Transl Med. 2019 Jul 10;11(500). pii: eaav5467. doi: 10.1126/scitranslmed.aav5467.

PMID:
31292266
5.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.

Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.

PMID:
30442503
6.

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.

Kubasch AS, Wehner R, Bazzurri S, Tunger A, Stasik S, Garzarolli M, Meinel J, Baretton G, Meier F, Thiede C, Schmitz M, Platzbecker U.

Blood Adv. 2018 Jun 12;2(11):1187-1190. doi: 10.1182/bloodadvances.2017014811. No abstract available.

7.

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.

Kubasch AS, Platzbecker U.

Cancers (Basel). 2018 May 24;10(6). pii: E158. doi: 10.3390/cancers10060158. Review.

8.

[Oculocutaneous and ocular albinism].

Kubasch AS, Meurer M.

Hautarzt. 2017 Nov;68(11):867-875. doi: 10.1007/s00105-017-4061-x. Review. German.

PMID:
29018889
9.

Laser Doppler Assessment of Vasomotor Axon Reflex Responsiveness to Evaluate Neurovascular Function.

Kubasch ML, Kubasch AS, Torres Pacheco J, Buchmann SJ, Illigens BM, Barlinn K, Siepmann T.

Front Neurol. 2017 Aug 14;8:370. doi: 10.3389/fneur.2017.00370. eCollection 2017. Review.

10.

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease (CAPTURE PD): Protocol for a Multicenter Study.

Siepmann T, Pintér A, Buchmann SJ, Stibal L, Arndt M, Kubasch AS, Kubasch ML, Penzlin AI, Frenz E, Zago W, Horváth T, Szatmári S Jr, Bereczki D, Takáts A, Ziemssen T, Lipp A, Freeman R, Reichmann H, Barlinn K, Illigens BM.

Front Neurol. 2017 May 26;8:212. doi: 10.3389/fneur.2017.00212. eCollection 2017.

11.

Randomized controlled trials - a matter of design.

Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T.

Neuropsychiatr Dis Treat. 2016 Jun 10;12:1341-9. doi: 10.2147/NDT.S101938. eCollection 2016. Review.

12.

Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO).

Hofmann SR, Kubasch AS, Range U, Laass MW, Morbach H, Girschick HJ, Hedrich CM.

Rheumatol Int. 2016 Jun;36(6):769-79. doi: 10.1007/s00296-016-3466-7. Epub 2016 Mar 21.

PMID:
27000045
13.

Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1β expression and release.

Hofmann SR, Kubasch AS, Ioannidis C, Rösen-Wolff A, Girschick HJ, Morbach H, Hedrich CM.

Clin Immunol. 2015 Dec;161(2):300-7. doi: 10.1016/j.clim.2015.09.013. Epub 2015 Sep 25.

PMID:
26404542

Supplemental Content

Loading ...
Support Center